Loading...
XHKG
1513
Market cap3.88bUSD
Apr 11, Last price  
25.80HKD
1D
-0.77%
1Q
0.78%
Jan 2017
24.88%
Name

Livzon Pharmaceutical Group Inc

Chart & Performance

D1W1MN
P/E
10.28
P/S
1.62
EPS
2.36
Div Yield, %
5.74%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
7.00%
Revenues
11.81b
-4.97%
1,626,145,8771,510,051,3571,748,108,3972,058,640,5732,595,847,0522,726,718,8953,162,915,2943,943,525,3054,618,680,0405,544,233,7776,620,516,5367,651,775,2858,530,968,5968,860,655,6709,384,695,83510,520,409,84212,063,863,27212,629,579,04712,430,038,32511,812,338,854
Net income
2.06b
+5.50%
107,891,938139,149,523508,451,06052,073,163481,578,249418,180,831359,369,880441,671,519487,502,351515,978,431622,641,033784,353,6074,428,684,5641,082,174,9051,302,875,4401,714,910,3901,775,683,2511,909,407,6871,953,650,8332,061,095,803
CFO
2.98b
-12.24%
161,070,286226,461,050248,553,495345,176,898494,877,099633,296,307708,201,336593,964,664439,986,525717,393,893927,788,4601,279,215,0371,315,865,4671,267,621,1811,767,162,8822,160,760,6061,902,328,1392,772,671,2953,394,202,1412,978,847,526
Dividend
Jul 08, 20241.48203 HKD/sh
Earnings
Apr 21, 2025

Profile

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
URL
https://www.livzon.com.cn/
IPO date
Oct 28, 1993
Employees
8,649
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,812,339
-4.97%
12,430,038
-1.58%
12,629,579
4.69%
Cost of revenue
8,982,159
9,544,891
10,432,055
Unusual Expense (Income)
NOPBT
2,830,180
2,885,147
2,197,524
NOPBT Margin
23.96%
23.21%
17.40%
Operating Taxes
501,661
485,066
375,010
Tax Rate
17.73%
16.81%
17.07%
NOPAT
2,328,519
2,400,082
1,822,513
Net income
2,061,096
5.50%
1,953,651
2.32%
1,909,408
7.53%
Dividends
(1,487,558)
(1,215,354)
Dividend yield
4.57%
4.00%
Proceeds from repurchase of equity
(369,704)
BB yield
1.13%
Debt
Debt current
2,455,000
1,860,010
1,632,681
Long-term debt
1,491,940
1,630,835
1,997,660
Deferred revenue
238,423
269,370
273,209
Other long-term liabilities
2
90,000
84,000
Net debt
(8,498,073)
(9,586,775)
(8,519,222)
Cash flow
Cash from operating activities
2,978,848
3,394,202
2,772,671
CAPEX
(820,452)
Cash from investing activities
(777,112)
Cash from financing activities
(1,733,411)
FCF
1,989,420
2,961,943
1,236,863
Balance
Cash
10,916,510
11,407,516
10,519,442
Long term investments
1,528,503
1,670,104
1,630,121
Excess cash
11,854,396
12,456,118
11,518,084
Stockholders' equity
13,716,137
13,736,755
13,569,858
Invested Capital
7,223,611
6,151,769
7,138,593
ROIC
34.82%
36.12%
25.88%
ROCE
14.68%
15.33%
11.66%
EV
Common stock shares outstanding
920,132
930,609
935,892
Price
38.00
8.54%
35.01
7.79%
32.48
-19.22%
Market cap
34,965,018
7.32%
32,580,615
7.18%
30,397,764
-19.10%
EV
27,510,358
23,718,048
22,938,773
EBITDA
3,405,316
3,725,471
2,849,848
EV/EBITDA
8.08
6.37
8.05
Interest
88,607
102,086
97,546
Interest/NOPBT
3.13%
3.54%
4.44%